Last reviewed · How we verify

NCT05641441

Radiosurgery Induced Ototoxicity in Patients Treated for a Vestibular Schwannoma

Recruiting now Last updated 13 January 2025
What this trial tests

trial testing Stereotactic radiosurgery in Vestibular Schwannoma in 258 participants. Currently enrolling.

Timeline
24 January 2023
Primary endpoint
15 November 2030
15 November 2030

Quick facts

Lead sponsorUniversity Hospital, Geneva
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment258
Start date24 January 2023
Primary completion15 November 2030
Estimated completion15 November 2030
Sites1 location across Switzerland

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Geneva

Who can join

18 and older, any sex, with Vestibular Schwannoma or Ototoxicity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators aim to study the impact of stereotactic radiosurgery, for the treatment of vestibular Schwannoma, on the cochlear, vestibular, gustatory, and facial nerve functions and compare it with a conservatively treated group. The predictive value of radiological tumor characteristics on hearing preservation and vestibular function will be also evaluated. Additionally, the investigators will invite patients with vestibular Schwannoma to fill out questionnaires to assess their quality of life.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Stereotactic radiosurgery

Trials testing the same drug.

Other recruiting trials for Vestibular Schwannoma

Currently open trials in the same condition.

Other University Hospital, Geneva trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05641441.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing